Anemia during treatment with peginterferon Alfa‐2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT‐2) trial

@article{Sulkowski2013AnemiaDT,
  title={Anemia during treatment with peginterferon Alfa‐2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT‐2) trial},
  author={M. Sulkowski and F. Poordad and M. Manns and Jean-Pierre Bronowicki and K. Rajender Reddy and Stephen A. Harrison and N. Afdhal and Heather L. Sings and Lisa D. Pedicone and Kenneth J. Koury and V. Sniukiene and Margaret H. Burroughs and Janice K. Albrecht and C. Brass and I. Jacobson},
  journal={Hepatology},
  year={2013},
  volume={57}
}
  • M. Sulkowski, F. Poordad, +12 authors I. Jacobson
  • Published 2013
  • Medicine
  • Hepatology
  • Boceprevir (BOC) added to peginterferon alfa‐2b (PegIFN) and ribavirin (RBV) significantly increases sustained virologic response (SVR) rates over PegIFN/RBV alone in previously untreated adults with chronic hepatitis C genotype 1. We evaluate the relationship of incident anemia with triple therapy. A total of 1,097 patients received a 4‐week lead‐in of PegIFN/RBV followed by: (1) placebo plus PegIFN/RBV for 44 weeks (PR48); (2) BOC plus PegIFN/RBV using response‐guided therapy (BOC/RGT); and… CONTINUE READING
    Safety of direct-acting antivirals in the treatment of chronic hepatitis C
    • 10

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 30 REFERENCES
    Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    • 6,407
    • PDF
    Boceprevir for previously treated chronic HCV genotype 1 infection.
    • 1,628
    • PDF